Delivering Improved Cardiac Safety Liabilities for Therapeutic Drugs Using the Contractome-AI

作为InoCardia Ltd的创始人，我运用30年的制药行业经验，于2013年将心脏工作环收缩性平台作为考文垂大学的分拆公司商业化。我的学术研究的商业化始于一个愿景，即制药行业对开发改进的生理相关模型来评估心脏收缩性的基本需求。这些讨论支持了学术研究项目，从而导致了基于组织/细胞的新型工作回路平台的开发，为更安全的药物开发开辟了新的途径。工作回路平台通过成立分拆公司InoCardia Ltd实现商业化，专注于提供心脏药物安全性评估服务。客户包括全球制药公司和药物发现生物技术公司。该公司已从外部融资机构（即InnovateUK）和风险资本家那里获得了英国和欧盟的投资资金。该公司目前提供世界上第一个非临床收缩性检测，提供卓越的预测性，目前正在革新心脏安全评估领域。要将学术研究理念转化为强大的商业产品，除了获取外部资金、保护知识产权、获得利益相关者的支持、学习商业语言以及了解市场需求和动态之外，还有很多东西需要学习。对我来说，不仅要成为我两个孩子的榜样，还要成为中学和大学学生的榜样，这一点非常重要。我真的相信“世界应该是你的”。我对商业/研究型教学充满热情，目前在理学士/理学硕士课程中教授“如何组建一家衍生公司”。我认为这个奖项是一个机会，让我能够激励女性科学家进行商业创新。虽然我是InoCardia的创始人和现任CSO，但我在3年前辞去了InoCardia的首席执行官一职，因为我觉得自己没有足够的信心或足够的商业经验来担任我的公司的首席执行官。我认为“女性创新奖”是一个重要的支持途径，可以帮助她们获得必要的技能，从而在未来晋升为首席执行官。我认为这个奖项的支持不仅会让我对自己作为领导者和技术创新者的能力更有信心，还有助于提高公司的知名度。这将使我能够促进InoCardia在制药行业的愿景，并为我提供一个商业支持网络，网络活动和吸引进一步的投资。

As the founder of InoCardia Ltd, I have applied 30 years' experience aligned to the pharmaceutical industry to commercialise the cardiac Work-Loop contractility platform as a spin-out company from Coventry University in 2013\.The commercialisation of my academic research started with a vision that there was a fundamental need within the Pharmaceutical Industry for the development of improved physiological relevant model to assess cardiac contractility. These discussions underpinned academic research projects leading to the development of the novel tissue/cell-based Work-Loop Platform that opened-up new pathways to safer drug development. The Work-Loop Platform was commercialised through the formation of the spin-out company InoCardia Ltd, focussing on providing a cardiac drug safety assessment service. Customers have included global pharmaceutical companies and drug discovery biotechs. The company has generated UK & EU investment funding from external funding bodies (i.e InnovateUK) and venture capitalists. The company currently offers the world's first nonclinical contractility assay which offers superior predictivity and is currently revolutionising the field of cardiac safety assessment. There is a lot to learn to translate an academic research idea into a robust commercial offering, in addition to accessing external funding, protecting intellectual property, getting buy-in from stakeholders, learning the language of business and understanding market requirements and dynamics.The notion of being a role model not only to my two children but also students in Schools and at University is extremely important to me. I truly believe that the "world should be your oyster". I am passionate about Business/Research inspired teaching and currently teach "How to form a spin out company", on BSc/MSc programmes. I see this award as an opportunity to enable me to inspire female scientists towards business innovation. Although I am the founder and current CSO for InoCardia, I stepped down from being InoCardia's CEO 3 years ago as I didn't feel that I had the confidence or adequate business experience to be CEO for my company. I see the Women in Innovation award an important supportive route to gain necessary skills to progress to CEO in the future. I think support via this award will not only help give me more confidence in my abilities as a leader and tech innovator but also helped raise the company's profile. It will enable me to promote InoCardia's vision within the Pharmaceutical Industry and provide me with the access to a network of business support, networking events and attract further investment.